{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:01Z","timestamp":1777934581004,"version":"3.51.4"},"reference-count":49,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common form of aggressive non-Hodgkin lymphoma. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first line chemoimmunotherapy, necessitating second-line salvage therapy. This has historically consisted of platinum-based chemotherapy regimens followed by autologous hematopoietic stem cell transplantation with curative intent for transplant-eligible patients or palliative chemotherapy for transplant-ineligible patients. In recent years there have been several new therapeutic agents approved for the treatment of relapsed\/refractory DLBCL, thereby expanding the therapeutic landscape. These agents include polatuzumab vedotin, tafasitamab, loncastuximab tesirine, selinexor, and anti-CD19 chimeric antigen receptor T-cell therapies such as axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. This review summarizes the pharmacology, efficacy, safety, dosing, and administration of new agents recently approved for the treatment of relapsed\/refractory DLBCL.<\/jats:p>","DOI":"10.1177\/10781552221096165","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T03:16:45Z","timestamp":1650943005000},"page":"1848-1858","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["New and emerging therapies for the treatment of relapsed\/refractory diffuse large B-cell lymphoma"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-9505","authenticated-orcid":false,"given":"Donald C.","family":"Moore","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Atrium Health, Levine Cancer Institute, Concord, NC, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Peery","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Virginia Commonwealth University Health, Richmond, VA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine A.","family":"Tobon","sequence":"additional","affiliation":[{"name":"Malignant Hematology Program, Moffitt Cancer Center, Tampa, FL, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Raheem","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Phoenix, AZ, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace S.","family":"Hwang","sequence":"additional","affiliation":[{"name":"Baylor St Luke\u2019s Medical Center, Houston, TX, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Alhennawi","sequence":"additional","affiliation":[{"name":"University of Cincinnati College of Pharmacy, Cincinnati, OH, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6572-1077","authenticated-orcid":false,"given":"Mitchell E.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Lymphoma Program, Hematology\/Oncology Division, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"bibr1-10781552221096165","unstructured":"SEER Cancer Stat Facts: Diffuse Large B-Cell Lymphoma. National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html. (access 22 November 2021)."},{"key":"bibr2-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"bibr3-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2"},{"key":"bibr4-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-322362"},{"key":"bibr5-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00900-7"},{"key":"bibr6-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403"},{"key":"bibr7-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01994"},{"key":"bibr8-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3911"},{"key":"bibr9-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"bibr10-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"bibr11-10781552221096165","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090597"},{"key":"bibr12-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1879-x"},{"key":"bibr13-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30026-2"},{"key":"bibr14-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"bibr15-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"bibr16-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30120-4"},{"key":"bibr17-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"bibr18-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"bibr19-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-205500"},{"key":"bibr20-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70128-2"},{"key":"bibr21-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"bibr22-10781552221096165","unstructured":"POLIVY (Polatuzumab Vedotin-piiq) [prescribing information]. South San Francisco, CA: Genentech, Inc.; June 2019."},{"key":"bibr23-10781552221096165","unstructured":"National Comprehensive Cancer Network. NCCN guidelines version 5.2021. B-cell lymphomas, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf (accessed 10 February 2022)."},{"key":"bibr24-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1080\/08820130500496878"},{"key":"bibr25-10781552221096165","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201000"},{"key":"bibr26-10781552221096165","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.168401"},{"key":"bibr27-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02635-9"},{"key":"bibr28-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-229039"},{"key":"bibr29-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5363"},{"key":"bibr30-10781552221096165","unstructured":"Monjuvi (tafasitamab) [prescribing information]. Boston, MA: Morphosys US Inc; June 2021."},{"key":"bibr31-10781552221096165","unstructured":"National Comprehensive Cancer Network. NCCN guidelines version 1.2022. Hematopoietic Growth Factors, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf (accessed 10 February 2022)."},{"key":"bibr32-10781552221096165","unstructured":"Zynlonta (loncastuximab tesirine) [prescribing information]. Murray Hill, NJ: ADC Therapeutics America; April 2021."},{"key":"bibr33-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118133"},{"key":"bibr34-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0711"},{"key":"bibr35-10781552221096165","unstructured":"Yescarta (axicabtagene ciloleucel) [prescribing information]. Santa Monica, CA: Kite Pharma Inc; April 2021."},{"key":"bibr36-10781552221096165","unstructured":"Kymriah (tisagenlecleucel) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2021."},{"key":"bibr37-10781552221096165","unstructured":"Breyanzi (lisocabtagene maraleucel) [prescribing information]. Bothell, WA: Bristol-Myers Squibb Company; February 2021."},{"key":"bibr38-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020"},{"key":"bibr39-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"bibr40-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"bibr41-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"bibr42-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"bibr43-10781552221096165","unstructured":"Xpovio (Selinexor) [prescribing information]. Newton, MA: Karyopharm Therapeutics Inc; August 2021."},{"key":"bibr44-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30120-4"},{"key":"bibr45-10781552221096165","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines version 1.2022. Antiemesis. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. (accessed 10 February 2022)."},{"key":"bibr46-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"bibr47-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"bibr48-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00931"},{"key":"bibr49-10781552221096165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221096165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221096165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221096165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:26:57Z","timestamp":1777688817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221096165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1177\/10781552221096165"],"URL":"https:\/\/doi.org\/10.1177\/10781552221096165","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]}}}